Profesionales médicos

A continuación, se enumeran los ensayos clínicos actuales.

Filtra esta lista de estudios por sede, estado, etc.

1. Comparing Retreatment Of 177Lu-DOTATATE PRRT Versus Everolimus In Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial

   Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   The purpose of this study is tol compare the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) to the usual approach of treatment with everolimus in patients who have previously received 177Lu-DOTATATE for midgut neuroendocrine tumor (NET) that has spread from where it first started (primary site) to other places in the body (metastatic) and that cannot be removed by surgery (unresectable).  

2. ICCaRE Consortium Pilot Project 1: Feasibility Of A Point Of Prostate Cancer Diagnosis Intervention For Newly Diagnosed Black Men

   Jacksonville, Fla.

   This study is being done to determine the acceptance and effectiveness of a virtual robot assistant model at a urology clinic.

3. Melodi Matrix™ In Breast Reconstruction

   Rochester, Minn.

   Prospective, multicenter, randomized, controlled trial evaluating the safety and effectiveness of an absorbable antibacterial matrix device in two stage prepectoral alloplastic breast reconstruction.

4. Ommaya Placement For Biomarker Collection

   Rochester, Minn.

   The purpose of this study is to determine the safety and feasibility of intra-operative Ommaya Reservoir placement during a clinically indicated tumor surgery in order to facilitate a longitudinal access to cerebrospinal fluid (CSF) for analysis of exploratory and future tumor biomarkers for individualized monitoring.

    

    

5. A Study To Evaluate The Surgical Removal Of Residual Brain Tumors Prior To Recurrence

   Rochester, Minn.

   The purpose of this study is to evaluate the safety and feasibility of surgical resection for pre-recurrent brain tumors. Eligible patients with surgically accessible latent tumors desiring surgical resection will be enrolled to prospectively track short- and long-term outcomes. Safety will be evaluated by quantifying rates of surgical morbidity as compared to patients undergoing RT after surgery, or no surgery for similar latent disease. Variables evaluated will include postoperative complications including death within 30 days, wound infection, length of hospital stay, and readmission rates.

    

    

6. A Dose-Escalation And Expansion Study Of Tacabrutideg (BGB-16673) In Participants With B-Cell Malignancies

   Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.

   Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

7. MC230813 A Study Of Golcadomide With Rituximab Prior To CAR-T With Relapsed Or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL)

   La Crosse, Wis., Mankato, Minn., Rochester, Minn., Eau Claire, Wis., Jacksonville, Fla., Scottsdale/Phoenix, Ariz., Albert Lea, Minn.

   The purpose of this study is to evaluate efficacy as measured by the disease control rate (CMR, PMR, and NMR) by Lugano 2014 PET-CT based assessment after 2 cycles of therapy.

8. A Study Of Biomarkers To Predict Cancer Therapy-related Cardiotoxicity

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

   The primary purpose of this study is to collect Biospecimens from patients who developed chemotherapy related cardiac toxicity (CRCT) and patients who are at a high risk for developing CRCT identified prior to the onset of therapy.

9. Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.

10. SULF1 and SULF2 Role in Cholangiocarcinoma

    Rochester, Minn.

    Cholangiocarcinoma (CCA) has key similarities with HCC, therefore, we hypothesize that Sulf1 and Sulf2 may also play roles in promotion of CCA progression.